I saw an article online yesterday that claimed that over 1% of Americans are using semaglutides for weight loss. Since these drugs suppress appetite, the article was about the possible impact on food retail. Since global warming promises to destroy a lot of arable land on the planet, as well as ocean fisheries, reducing food consumption by overweight people strikes me as an unalloyed good. Since obesity is a risk factor for cancer, heart disease, diabetes and joint damage, maybe semaglutides will also reduce healthcare costs in America. This is starting to shape up like statins, anti-hypertensives and antibiotics for peptic ulcers–relatively risk-free pharmacology with transformative health outcomes.
Topics:
Joel Eissenberg considers the following as important: Healthcare, Hot Topics
This could be interesting, too:
NewDealdemocrat writes March JOLTS report: declines in everything, fortunately including layoffs
NewDealdemocrat writes Manufacturing treads water in April, while real construction spending turned down in March (UPDATE: and heavy truck sales weren’t so great either)
NewDealdemocrat writes Repeat home sale prices accelerated in February (but don’t fret yet)
NewDealdemocrat writes Looking at historical “mid cycle indicators” – what do they say now?
I saw an article online yesterday that claimed that over 1% of Americans are using semaglutides for weight loss. Since these drugs suppress appetite, the article was about the possible impact on food retail.
Since global warming promises to destroy a lot of arable land on the planet, as well as ocean fisheries, reducing food consumption by overweight people strikes me as an unalloyed good.
Since obesity is a risk factor for cancer, heart disease, diabetes and joint damage, maybe semaglutides will also reduce healthcare costs in America. This is starting to shape up like statins, anti-hypertensives and antibiotics for peptic ulcers–relatively risk-free pharmacology with transformative health outcomes.